Abstract Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease severity, response to treatment, and organ damage, the pathogenesis of which includes immunological mechanisms that are driven by both genetic and environmental factors. There are clear differences in the pathogenesis of SLE between patients of different ancestral backgrounds, including differences in genetic risk factors, immunological parameters, and clinical manifestations. Patients with high and low levels of type I interferon (IFN) in circulation represent one major biological subset within SLE, and these two groups of patients are present in all ancestral backgrounds. Genetic factors, autoantibodies, and levels of other cytokines all differ between high and low IFN patients. This distinction has also been important in predicting response to treatment with anti-type I IFN therapies, providing a precedent in SLE for biological subsets predicting treatment response. This review highlights some recent developments in defining biological subsets of SLE based on disease pathophysiology, and we speculate how this improved knowledge of disease heterogeneity will inform our efforts to personalize therapy in this disease.
Introduction
Systemic lupus erythematosus (SLE) is a chronic inflammatory, immune-mediated disease with heterogeneous clinical manifestations that affects 0.1% of the general population [1] . While SLE affects all populations worldwide, it is more common in some. For instance, SLE is three to four times more common in people with nonEuropean ancestry than in European ancestry in the USA [1] . The reasons for this disparity remain unclear, but it seems likely that differences in molecular pathogenesis and disease biology contribute to this phenomenon [1] .
SLE is highly heterogeneous clinically-a broad array of disease manifestations are observed, ranging from rash and arthritis to severe organ-and life-threatening disease [2] . This heterogeneity in SLE is particularly challenging in clinical practice, as we do not have good predictors of disease course currently, and we do not know which patients will develop specific disease features [3] , which is likely because we do not have a complete understanding of the pathogenesis of SLE in humans. A number of immunological mechanisms have been implicated, including dysregulation of the innate immune system, diminished clearance of apoptotic cells, and loss of self-tolerance by the adaptive immune system. These changes in the immune system result from an interaction of genetic, environmental, and hormonal risk factors [4] .
While our knowledge of human SLE pathogenesis is incomplete, recent studies have documented many differences in the molecular features of SLE that distinguish important patient subgroups [5] . The genetic risk factors that predispose to SLE differ between world populations, and there are many differences in the molecular immune system between patients. In this review, we highlight some recent developments in defining biological subsets of SLE based on disease pathophysiology, and speculate how this knowledge may be useful for the development of effective targeted therapies for specific SLE phenotypes.
Clinical Differences Related to Ancestral Background
SLE has been described in each of the six populated continents: Europe, North America, South America, Africa, Asia, and Australia [6] . It is less commonly reported in Africa, but common in African descendants around the world [3] . Incidence and prevalence rates in African or Asian ancestry are approximately two to three times higher than in European ancestry populations [7] [8] [9] [10] [11] [12] [13] . The disease is also more common among Aboriginal than non-Aboriginal Australians [14, 15] , and in First Nations or Native American groups in Canada and the USA [16, 17] . Differences in the prevalence of clinical manifestations of SLE have been noted for many years. For example, African American (AA) SLE patients have more nephritis than European American (EA) patients [18] [19] [20] [21] . SLE patients of AA descent experience increased morbidity and mortality compared with EA patients, largely related to the increased frequency and severity of nephritis [22] . Table 1 lists differences in the prevalence of specific clinical manifestations according to ancestral background in SLE.
Immunological Differences Related to Ancestral Background
Given the differences in clinical disease outlined in Sect. 2, it is not surprising that immunological differences exist between SLE patients of different ancestral backgrounds. One such difference is in the prevalence of anti-Smith (anti-Sm) and anti-ribonucleoprotein binding protein (anti-RNP) autoantibodies in AA versus EA SLE patients. Both of these autoantibodies are approximately five-fold more common in AA than in EA SLE patients [23] . Interferon (IFN)-a is a primary pathogenic factor in human SLE [24] . High levels of type I IFN can be observed in 40-50% of SLE patients [25] and this finding is relatively stable over time [26] , suggesting that there is a high IFN subgroup of patients within SLE. Supporting a causal role in disease, recombinant IFN-a therapy has resulted in de novo SLE [27, 28] , which typically resolves when the IFN therapy is discontinued [29] . Elevated type I IFN is another immunological feature of SLE that differs between populations [25] . European ancestry SLE patients were found to have lower serum type I IFN levels than non-European ancestry patients in a study that involved over 1000 SLE patients of EA, AA, or Hispanic American ancestry, a finding that was independent of other clinical variables [25] . A follow-up study used genetic markers to quantitatively designate ancestry [30] . This study showed that African ancestry was most strongly associated with the production of anti-RNP autoantibodies, and the presence of anti-RNP was associated with increased peripheral type I IFN in these patients [30] . When IFN-induced gene expression patterns are studied in blood cells from SLE patients of different ancestral backgrounds, increased type I IFN-induced gene expression was dependent on anti-RNA-binding protein autoantibodies (anti-Ro, anti-La, anti-Sm, or anti-RNP) in AA SLE Renal disease [3, 79] Asian Renal disease [80] European American Photosensitivity Malar rash [81] a Subjects with ancestry from Native American populations patients [31] . In EA SLE patients, increased IFN-induced gene expression was observed in subjects with and without anti-RNA-binding protein autoantibodies, suggesting that the regulation of IFN-induced gene expression in SLE patients differs between ancestral backgrounds [31] . Diversity in the IFN signature by ancestral background also extends to various cell types in peripheral blood. In a study of gene expression in CD4 T cells, CD8 T cells, monocytes, and B cells in AA and EA SLE patients and controls, different IFN-induced genes were expressed in the various cell types. Thus, while each cell type demonstrated an IFN signature, the particular transcripts making up that signature differed to a large degree between cell types [32] . Interestingly, there was a greater degree of correlation in the strength of the IFN signature across cell types in AA patients than in EA patients, again suggesting differences in IFN pathway regulation between ancestral backgrounds [32] . Studies have also compared the circulating level of B cell activating factor [BAFF, or B lymphocyte stimulator (BlyS)] in SLE patients between ancestral backgrounds [33] . BAFF levels were shown to be higher in AA SLE patients than in EA SLE patients. These data could identify patient subgroups that may respond to BAFF inhibitors such as belimumab. Interestingly, BAFF is induced by type I IFN, and is thus considered an IFNinduced gene [34] . While in vitro data may not always predict correlations between cytokine levels in circulation in humans in vivo, in this case a strong correlation was observed between circulating BAFF levels and type I IFN levels in both ancestral backgrounds [33] . This finding could suggest that blocking type I IFN could also block BAFF in the same patients, if the type I IFN is a major factor inducing BAFF in SLE. Tumor necrosis factor (TNF)-a is another cytokine that has been studied in a large multi-ancestral group of SLE patients [35] . TNF-a levels are not significantly different between SLE patients of different ancestral backgrounds, and the levels of TNF-a were not correlated with type I IFN in the patients [35] .
Genetic Predisposition and Contribution to Diversity
Familial aggregation studies in lupus support the idea that SLE has a genetic basis, and that inheritance is complex in most SLE cases [36] . The concordance rate of lupus in monozygotic twins (24-58%) is higher than dizygotic twins (2-5%), supporting the idea that genetics play a large role in the predisposition to SLE [5] . Some monogenic causes of SLE have been reported [37, 38] , but these are rare cases and it seems that for most patients the disease is caused by multiple risk factors acting in concert. Genome-wide association studies (GWAS) have greatly increased our knowledge of the genetic basis of SLE in recent years, and these studies also support the idea of multi-factorial inheritance. To date, GWAS are based on European and Asian populations, and thus the findings of these studies are likely to be most relevant for these ancestral backgrounds [39, 40] . When alleles discovered in European ancestry were tested for association in AA SLE patients, there were some alleles that overlapped and some that did not [41] . A GWAS in AA SLE patients is currently underway, and it is likely that this will identify some novel alleles that have not been observed in other ancestral backgrounds.
The idea that different SLE-risk genes are related to different disease manifestations in SLE is supported by the results of several studies. For example, polymorphisms in integrin subunit alpha M (ITGAM), signal transducer and activator of transcription 4 (STAT4), apolipoprotein L1 (APOL1), platelet-derived growth factor receptor alpha (PDGFRA), and hyaluronan synthase 2 (HAS2) have been associated with greater risk of nephritis in SLE patients [5, [42] [43] [44] [45] [46] . While some of these polymorphisms, such as ITGAM and STAT4, are also general SLE risk factors, APOL1, PDGFRA, and HAS2 are genes that seem to be specifically associated with risk of nephritis in SLE and are not general SLE-risk genes [47] .
Autoantibodies also demonstrate familial aggregation in SLE families, in both SLE-affected and -unaffected family members, suggesting a genetic basis for autoantibody formation [23] . Polymorphisms in IFN regulatory factor (IRF)5, IRF7, STAT4, and other known SLE-risk loci have been associated with the production of particular autoantibodies [44, [48] [49] [50] [51] , further supporting the case that autoantibody formation in SLE has a genetic component, and that subsets of patients defined by autoantibodies are genetically different. We have previously shown that many first-degree relatives of SLE patients had significantly higher serum IFN-a levels than healthy unrelated individuals [52, 53] . These data suggest that IFN-a is a heritable risk factor in SLE, and thus genetic factors that lead to high IFN-a may be concentrated in lupus families [52] . The differences in IFN-a level between patients of different ancestral backgrounds could, therefore, relate to genetic differences between populations. Familial studies have also demonstrated similar results for TNF-a as well as interleukin-10 [54, 55] , further supporting the idea that genetic thresholds for cytokine production and signaling contribute to the risk of SLE.
Interferon Regulatory Factors as an Example of Genetics Driving Diversity in Human Systemic Lupus Erythematosus (SLE)
IRF5 is a transcription factor that can induce type I IFNrelated and other inflammatory gene expression downstream of Toll-like receptor engagement [56] , and variants in the IRF5 gene have been associated with risk of SLE [38] [39] [40] [41] [42] . SLE patients carrying the IRF5 risk haplotype have higher serum IFN-a, and are also more likely to have either anti-double-stranded DNA (anti-dsDNA) or anti-RNP antibodies [48, 57] . Interestingly, the impact of the IRF5 genotype on type I IFN levels was dependent on having these autoantibodies, and thus the associations between genotype and immune system phenotypes suggest a pathogenic model [48] . In this model, the immune complexes made by the autoantibodies serve as an endogenous trigger for type I IFN production, and longterm stimulation of the pathway by immune complexes in combination with the SLE-risk IRF5 isoform results in over-production of IFN and the risk of SLE [58] . Genetic association data would support this model, as the risk of SLE in relation to IRF5 is largely confined to this group of anti-Ro and/or anti-dsDNA autoantibody positive, high IFN patients [48] . While IRF5 haplotypes are similar across ancestral backgrounds, the SLE-risk haplotype was not found in African populations, and was found in AA populations at a rate that would be expected due to admixture [48] . These data could suggest that the SLE-risk haplotype was of European origin, or possibly that this haplotype had become extinct in Africa. Recent studies of ancient Neanderthal DNA have supported a third idea-that the SLE-risk haplotype of IRF5 is actually of Neanderthal origin [59] . This surprising result explains the geographic restriction of the haplotype, as it occurs in populations that overlapped with the Neanderthal range. It also provides a fascinating example of pre-Homo sapiens evolution affecting the risk of autoimmune disease in modern human populations. Some modern human genetic variations in Toll-like receptors have also recently been shown to originate from Neanderthals and another early hominid population, the Denisovans [60, 61] , suggesting that the diversity in our immune system genes extends far beyond the recent evolution of Homo sapiens.
IRF7 is a transcription factor that is related to IRF5, functioning to induce type I IFN and inflammatory gene expression downstream of Toll-like receptors. Genetic variations in IRF7 have also been associated with SLE [62] . A similar model is observed in which the IRF7 gene variant is associated with autoantibody formation as well as higher type I IFN levels in circulation, and the effect of IRF5 and IRF7 genotypes together was additive [50] . Interestingly, the particular genetic polymorphism and autoantibody differed between ancestral backgrounds, again suggesting human diversity within a shared mechanism of disease, parallel to that observed with IRF5.
Type I Interferon as a Method to Discover Novel Genes in SLE
The studies discussed in Sect. 5 outline functional work determining the impact of known susceptibility loci on IFN levels and other immune phenotypes in SLE. Given that type I IFN is a pathogenic factor in SLE, another approach is to screen for genes related to high IFN in SLE patients. Studies using this approach have utilized a case-case design, comparing patients with high IFN with those with low IFN, which should identify genes related to high IFN in SLE while excluding those genes that are not related to IFN. This study design reduces the complexity and heterogeneity between the comparator groups, resulting in greater statistical power for discovery. Using this approach, studies have identified a number of novel loci related to IFN in SLE patients, including protein kinase, cyclic guanosine monophosphate (cGMP)-dependent, type I (PRKG1), purine nucleoside phosphorylase (PNP), and others [63] [64] [65] . PRKG1 codes for the soluble isoforms of the cGMPdependent protein kinase (Ia and Ib). Co-expression analyses in public datasets support the importance of this gene in immune cell types such as dendritic cells and natural killer (NK) cells [63] , and coding change mutation in this gene has been linked to cutaneous T cell lymphoma [66] . PNP is involved in nucleotide salvage and homeostasis, and human deficiency of the PNP gene results in a disorder characterized by defective T and B cell immunity and autoimmune features such as immune-mediated thrombocytopenia and others [67] . The polymorphism identified does not cause complete deficiency, but, given the above, the gene is of high interest in SLE pathogenesis. The associations between PRKG1 and PNP and type I IFN in SLE were limited to patients of European ancestry. In other backgrounds, different genes have been linked to the high IFN phenotype, such as LRRC20, ANKS1A, and EPHA5 [64, 65] . Thus, these data again emphasize that while high IFN is observed in SLE patients of various ancestral backgrounds, it is likely that different factors result in a high IFN phenotype in the different ancestral backgrounds. These differences are likely to be important as we begin to target the type I IFN pathway therapeutically in SLE.
A number of therapies targeting various aspects of the immune response are currently in development for SLE [68] . Ideally, these would improve upon the current standard of non-specific immunosuppression and correct some of the specific abnormalities of the immune system in SLE patients [68] . Some case series and open-label studies have reported successful treatment of lupus nephritis with rituximab. Reduction of disease activity and proteinuria was observed in patients with lupus nephritis receiving rituximab along with other immunosuppressants such as azathioprine, mycophenolate mofetil (MMF), cyclophosphamide, and corticosteroids [69] [70] [71] . Clinical improvements have also been reported when using rituximab in membranous lupus nephritis [72] . Despite these encouraging early results, rituximab did not meet endpoints in controlled trials; however, study design issues also may have played a role as the placebo group was receiving numerous background immunosuppressive medications, including a proportion on medium-to high-dose glucocorticoids [73] . It is possible that rituximab has no effect in SLE, and that the early smaller and less well-controlled studies were misleading. Many clinicians are still prescribing rituximab for SLE, however, and another possibility is that the medication works better in some subsets of patients that were present in the smaller studies in a greater proportion than in the larger controlled trials. This issue illustrates a major difficulty in applying personalized approaches to trials-conventional trial design is not optimized to identify important subset effects that could enable more personalized therapies [68] .
Ancestry is one important source of diversity in response to therapy. For example, response to MMF varies by ancestral background, with a large study showing that AA and Hispanic American SLE patients were more likely to respond [74] . Another study has suggested that Asian SLE patients might respond to lower doses of MMF than subjects with European ancestry [75] . While early belimumab studies suggested better responses in European ancestry [76] , no difference was observed in follow-up studies between EA, AA, and other ancestral backgrounds from the USA in terms of response at 0-6 months [77] . In this study, the response rate remained similar between EA and AA patients at 18-24 months [77] .
Less is currently known about how biological phenotype impacts response to treatment in SLE, and this represents a critical frontier that would likely be more promising than stratifying patients by ancestral background [68] . Both of the two phase II trials of anti-IFN-a drugs in SLE were characterized by subset effects, in which the baseline level of type I IFN was an important predictor of response to therapy [78] . This type of pre-treatment pathway assessment holds great promise for rationally directing therapies, and hopefully this represents the future of SLE treatment.
Conclusions
Clinical practice and molecular studies strongly support the idea that SLE patients represent different pathogenic subsets, from genetics to immune phenotype to the clinical manifestation of disease. These are impacted somewhat by ancestral background, which likely represents differential recent human evolution in the immune system, and there is also evidence of early hominid genetic contribution to the immune pathways implicated in SLE. Most of these common inherited immune system polymorphisms likely evolved and were maintained in the genome to assist in defending us from pathogens, but can also predispose to autoimmunity in certain situations and combinations. This fascinating degree of human diversity of the immune system cannot be ignored, and it seems likely that we will have to include the concept of biological subsets in clinical trial design if we are to be successful in many of the heterogeneous autoimmune diseases such as SLE. However, it is not easy to generalize at exactly which stage of a trial to incorporate subsets, and to what degree. It is likely that these decisions would have to be based on the animal and human pre-clinical in vitro data as well as knowledge of the human biological diversity such as is reviewed here. It is critical for us to understand and define biological heterogeneity in SLE if we are to implement personalized therapies, and there is a good deal of exciting work in this area that will facilitate these efforts and hopefully improve treatment for patients with this difficult disease.
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